Breaking Finance News

finnCap disclosed Avacta Group PLC (LON:AVCT), supporting its price target at 200.00GBX earlier today

Having a price of 67.25GBX, Avacta Group PLC (LON:AVCT) traded 0.00% even on the day. With the last stock price down -10.78% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.02% over the same period. AVCT has recorded a 50-day average of 72.88GBX and a two hundred day average of 80.14GBX. Trade Volume was down over the average, with 3,000 shares of AVCT changing hands under the typical 27,417

Reporting a potential upside of 1.97%, finnCap hold steady the price target of Avacta Group PLC (LON:AVCT) at 200.00GBX

On 10/10/2017, finnCap released a statement about Avacta Group PLC (LON:AVCT) maintained the target price at 200.00GBX that suggested an upside of 1.78%.

Recent Performance Chart

Avacta Group PLC (LON:AVCT)

Avacta Group PLC has with a one year low of 60.00GBX and a one year high of 98.00GBX and has a market capitalization of 0 GBX.

A total of 1 brokerage has issued a ratings update on Avacta Group PLC. zero brokerages rating the company a strong buy, zero brokerages rating the company a buy, zero brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of 160.00GBX.

Brief Synopsis On Avacta Group PLC (LON:AVCT)

Avacta Group plc is a biotechnology company. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies. Affimer technology is based on a small protein that can be generated to bind with specificity and affinity to a range of targets to enable diagnostics, research assays and therapeutics. Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *